Magellan Health Services Reports First Quarter 2012 Financial Results

Magellan Health Services Inc. (NASDAQ: MGLN) today reported financial results for the first quarter 2012, as summarized below. For the quarter ended March 31, 2012, the company reported net revenue of $773.2 million, segment profit of $55.4 million, and net income of $20.8 million or $0.75 per diluted common share. Segment profit represents income from operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes.

Financial Results
           
Three Months Ended March 31
    Increase/
(Millions, except per share results)   2012   2011   (Decrease)
Revenue $773.2 $692.8 11.6%
Segment Profit 55.4 75.7 (26.8)%
Net Income 20.8 34.3 (39.4)%
Earnings per Share 0.75 1.02 (26.5)%
 

As of March 31, 2012, the company had unrestricted cash and investments of $202.7 million.

“During the first quarter, we had solid financial results and made important strides in executing our growth strategy,” said René Lerer, M.D., chairman and chief executive officer. “We implemented two new behavioral health customers, Blue Shield of California and the state of Louisiana, and entered into an agreement with Coventry Health Care to extend our existing contract and establish a nationwide preferred radiology management relationship.

“I am particularly pleased with the progress on our two key strategic initiatives in Medicaid and pharmacy. The goal of our Medicaid strategy is to leverage our unique skills to manage specialty populations on a full medical risk basis - not just from a behavioral, pharmacy or radiology perspective. This is initially being implemented in key geographic areas where we have either formed joint ventures or are building physical health capabilities in order to provide integrated care for these individuals. It represents one of the most significant business opportunities to fuel our future growth and profitability. In pharmacy, we are investing in new products to help customers manage the total drug spend for both the medical and pharmacy benefit. We are moving aggressively to pursue growth.”

“Among our business segments, the public sector behavioral health and pharmacy segments performed well,” said Karen S. Rohan, Magellan’s president. “The radiology segment experienced margin contraction as business was repriced, and in the commercial behavioral segment we continue to address cost of care issues, and expect improvement in results over the balance of the year. We have been aggressively pursuing product innovation based on our strong clinical and technical expertise, and during the quarter, began marketing several new products.”

Outlook

“Our performance gives us a solid foundation for the rest of the year,” said Jonathan N. Rubin, chief financial officer. “We were also pleased that Standard & Poor’s increased our counterparty credit rating to BBB-, which is considered investment grade. This upgrade is in recognition of our track record of operating performance and strong cash flows, the financial strength of the organization and future market opportunities. Magellan remains well positioned with sound fundamentals to continue executing our growth strategy.

“We are reaffirming our guidance for 2012, which calls for net revenue in the range of $3.2 billion to $3.4 billion, and net income in the range of $91 million to $109 million, which translates into diluted earnings per share in the range of $3.25 to $3.89. Additionally, we expect segment profit for 2012 to be in the range of $240 million to $260 million, and a net increase in unrestricted cash and investments of between $91 million and $136 million.”

Earnings Results Conference Call

Management will host a conference call at 10:00 a.m. Eastern Time on Friday, April 27, 2012. To participate in the conference call, interested parties should call 1-888-566-8408 and reference the pass code First Quarter Earnings Call 2012 approximately 15 minutes before the start of the call. The conference call will also be available via a live Webcast at Magellan’s investor relations page at www.MagellanHealth.com.

About Magellan Health Services: Headquartered in Avon, Conn., Magellan Health Services Inc. is a leading specialty health care management organization with expertise in managing behavioral health, radiology and specialty pharmaceuticals, as well as public sector pharmacy benefits programs. Magellan delivers innovative solutions to improve quality outcomes and optimize the cost of care for those we serve. As of March 31, 2012, Magellan’s customers include health plans, employers and government agencies, serving approximately 33.8 million members in our behavioral health business, 16.1 million members in our radiology benefits management segment, and 6.2 million members in our medical pharmacy management product. In addition, the specialty pharmaceutical segment served 41 health plans and several pharmaceutical manufacturers and state Medicaid programs. The company’s Medicaid Administration segment served 24 states and the District of Columbia. For more information, visit www.MagellanHealth.com.

Cautionary Statement

This release contains forward-looking statements within the meaning of the Securities Exchange Act of 1934 and the Securities Act of 1933, as amended, which involve a number of risks and uncertainties. All statements, other than statements of historical information provided herein, may be deemed to be forward-looking statements including, without limitation, statements regarding estimates of 2012 net revenue, net income, segment profit, earnings per share, changes in unrestricted cash and investments, and strategy. These statements are based on management’s analysis, judgment, belief and expectation only as of the date hereof, and are subject to uncertainty and changes in circumstances. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “may,” “should,” “could,” “estimate,” “intend” and other similar expressions are intended to identify forward-looking statements. Actual results could differ materially due to, among other things, the possible election of certain of the company’s customers to manage the health care services of their members directly; changes in rates paid to and/or by the company by customers and/or providers; higher utilization of health care services by the company’s risk members; delays, higher costs or inability to implement new business or other company initiatives; the impact of changes in the contracting model for Medicaid contracts; termination or non-renewal of customer contracts; the impact of new or amended laws or regulations; governmental inquiries; litigation; competition; operational issues; health care reform; and general business conditions. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included within the company’s Annual Report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission on February 28, 2012, and the company’s subsequent Quarterly Report on Form 10-Q expected to be filed with the Securities and Exchange Commission and posted on the company’s website later today. Readers are cautioned not to place undue reliance on these forward-looking statements. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date of this release. Segment profit information referred to herein may be considered a non-GAAP financial measure. Further information regarding this measure, including the reasons management considers this information useful to investors, are included in the company’s most recent Annual Report on Form 10-K and on subsequent Form 10-Qs.
MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
(In thousands, except per share amounts)
   
 
 
Three Months Ended March 31,
2011

2012 (1)
 
Net revenue $ 692,755 $ 773,213
 
Cost and expenses:
Cost of care 433,700 505,293
Cost of goods sold 56,519 81,038
Direct service costs and other operating expenses (2) 131,567 136,589
Depreciation and amortization 13,952 14,781
Interest expense 471 600
Interest income   (815 )   (412 )
  635,394     737,889  
Income before income taxes 57,361 35,324
Provision for income taxes   23,063     14,534  
Net income 34,298 20,790
Other comprehensive income (3)   97     173  
Comprehensive income $ 34,395   $ 20,963  
 
Weighted average number of common shares outstanding — basic   33,051     27,199  
Weighted average number of common shares outstanding — diluted   33,656     27,747  
 
Net income per common share — basic $ 1.04   $ 0.76  
Net income per common share — diluted $ 1.02   $ 0.75  
 

(1)
 

For a more detailed discussion of Magellan's results for the quarterly period ended March 31, 2012, refer to the Company's Quarterly Report on Form 10-Q, which will be filed with the SEC on April 27, 2012, and the live broadcast or taped replay of the Company's earnings conference call on April 27, 2012, which will be available at www.MagellanHealth.com.

 

(2)
 

Includes stock compensation expense of $4,778 and $5,102 for the three months ended March 31, 2011 and 2012, respectively.
 

(3)
 

Amounts are net of income tax provision of $61 and $111 for the three months ended March 31, 2011 and 2012, respectively.
 
MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
   
 
 
Three Months Ended March 31,
2011

2012 (1)
 
Cash flows from operating activities:
Net income $ 34,298 $ 20,790
 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 13,952 14,781
Non-cash interest expense 107 177
Non-cash stock compensation expense 4,778 5,102
Non-cash income tax (benefit) expense (472 ) 3,017
Non-cash amortization on investments 3,228 1,760

Cash flows from changes in assets and liabilities, net of effects from acquisitions of businesses:
Restricted cash (2) 15,623 852
Accounts receivable, net (6,144 ) (12,106 )
Pharmaceutical inventory (17,878 ) (3,502 )
Other assets 14,448 6,437
Accounts payable and accrued liabilities (25,792 ) (26,724 )
Medical claims payable and other medical liabilities (10,122 ) 19,201
Other   3,242     (216 )
Net cash provided by operating activities   29,268     29,569  
 
Cash flows from investing activities:
Capital expenditures (10,090 ) (14,505 )
Purchase of investments (179,772 ) (61,977 )
Maturity of investments 73,015 97,168
Acquisitions and investments in businesses, net of cash acquired   (274 )   -  
Net cash (used in) provided by investing activities   (117,121 )   20,686  
 
Cash flows from financing activities:
Proceeds from issuance of equity 20,000 -
Payments to acquire treasury stock (122,071 ) -
Proceeds from exercise of stock options and warrants 8,016 2,197
Other   (563 )   (743 )
Net cash (used in) provided by financing activities   (94,618 )   1,454  
 
Net (decrease) increase in cash and cash equivalents (182,471 ) 51,709
Cash and cash equivalents at beginning of period   337,179     119,862  
Cash and cash equivalents at end of period $ 154,708   $ 171,571  
 

(1)
 

The Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2012 will be filed with the SEC on April 27, 2012.
 

(2)
 

Includes the net shift of restricted funds between cash and investments that results in an operating cash flow change that is directly offset by an investing cash flow change. During the three months ended March 31, 2011 and 2012, restricted investments of $13,238 and $4,419, respectively, were shifted to restricted cash that resulted in an operating cash flow use.

 
MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES
CONSOLIDATED OPERATING RESULTS BY BUSINESS SEGMENT
(Unaudited)
(In thousands)
   
 
 
Three Months Ended March 31,
2011

2012 (1)
 
Net revenue
- Commercial $ 150,035 $ 180,524
- Public Sector 350,516 388,888
- Radiology Benefits Management 89,212 76,857
- Specialty Pharmaceutical Management 70,230 100,198
- Medicaid Administration (2) 53,293 47,854
- Elimination (2)   (20,531 )   (21,108 )
Total net revenue   692,755     773,213  
 
Cost of care
- Commercial 75,313 112,172
- Public Sector (2) 304,921 344,312
- Radiology Benefits Management 54,717 50,410
- Medicaid Administration 19,280 19,507
- Elimination (2)   (20,531 )   (21,108 )
Total cost of care   433,700     505,293  
 
Cost of goods sold - Specialty Pharmaceutical Management   56,519     81,038  
 
Direct service costs and other operating expenses
- Commercial 37,807 42,362
- Public Sector 16,976 20,597
- Radiology Benefits Management 16,705 13,486
- Specialty Pharmaceutical Management 6,012 6,467
- Medicaid Administration 25,986 22,552
- Corporate   28,081     31,125  
Total direct service costs and other operating expenses   131,567     136,589  
 
Stock compensation expense (3)
- Commercial (250 ) (267 )
- Public Sector (222 ) (287 )
- Radiology Benefits Management (482 ) (400 )
- Specialty Pharmaceutical Management (126 ) (172 )
- Medicaid Administration (23 ) (58 )
- Corporate   (3,675 )   (3,918 )
Total stock compensation expense   (4,778 )   (5,102 )
 
Segment profit (loss)
- Commercial 37,165 26,257
- Public Sector 28,841 24,266
- Radiology Benefits Management 18,272 13,361
- Specialty Pharmaceutical Management 7,825 12,865
- Medicaid Administration 8,050 5,853
- Corporate and Elimination   (24,406 )   (27,207 )
Total segment profit $ 75,747   $ 55,395  
 
 

Reconciliation of segment profit to income before income taxes:
Segment profit $ 75,747 $ 55,395
Stock compensation expense (4,778 ) (5,102 )
Depreciation and amortization (13,952 ) (14,781 )
Interest expense (471 ) (600 )
Interest income   815     412  
Income before income taxes $ 57,361   $ 35,324  
 

(1)
 

The Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2012 will be filed with the SEC on April 27, 2012.
 

(2)
 

Public Sector has subcontracted with Medicaid Administration to provide pharmacy benefits management services on a limited risk basis for one of Public Sector's customers. As such, revenue and cost of care related to this intersegment arrangement are eliminated.

 

(3)
 

Stock compensation expense is included in direct service costs and other operating expenses; however, this amount is excluded from the computation of segment profit since it is managed on a consolidated basis.

 

Copyright Business Wire 2010

If you liked this article you might like

Healthcare Stocks Mixed Following Senate Vote to Proceed on Healthcare Bill

Healthcare Stocks Mixed Following Senate Vote to Proceed on Healthcare Bill

Magellan Shares Up Strong After Shelling Out $400M to Buy Senior Whole Health

Magellan Shares Up Strong After Shelling Out $400M to Buy Senior Whole Health

UnitedHealth to Test Durability of 2017's Strong Start

UnitedHealth to Test Durability of 2017's Strong Start

Today's Strong And Under The Radar Stock Is Magellan Health (MGLN)

Today's Strong And Under The Radar Stock Is Magellan Health (MGLN)

Insider Trading Alert - MGLN, AZZ And DY Traded By Insiders

Insider Trading Alert - MGLN, AZZ And DY Traded By Insiders